![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Pharmacological observations that potent peptidic glucagon antagonists and antiglucagon antibodies are capable of lowering glucose levels in plasma, suggest that small molecule glucagon antagonists are strong candidates for the treatment of diabetes. Several classes of compounds have been identified that possess potent affinity for the human glucagon receptor. To date, one such molecule has advanced into clinical trial. This review will focus on published patent applications describing non-peptidic glucagon antagonists.